Side-chain modified vitamin D analogs including 20-Epi-22-oxa-24a-,26a,27a-trihomo-1 alpha,25-dihydroxyvitamin D-3 (KH1060), and 1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin D-3 (MC903) were originally designed to aid in the treatment of hyperproliferative disorders including psoriasis and cancer. Here we demonstrate that these analogs, as well as the 6-cis-locked conformer, 1 alpha,25- dihydroxy-lumisterol(3) (JN) prime NB4 cells for monocytic differentiation. Previously, the action of MC903 and KH1060 was presumed to be mediated by the nuclear vitamin D receptor (VDRnuc). Differentiation in response to all analogs was shown to be inhibited by 1 beta,25-dihydroxyvitamin D-3 (HL), the antagonist to the nongenomic activities of 1,25D(3). These data suggest that although MC903 and KH1060 may bind the VDRnuc, that the differentiative activities of these agents requires nongenomic signaling pathways. Here we show that 1 alpha,25(OH)(2)-d(5)-previtamin D-3 (HF), JN, KH1060, and MC903 induce expression of PKC alpha and PKC delta and translocation of both isoforms to the particulate fraction, and PRC alpha to the nuclear fraction. The full differentiation response with combinations of analogs and TPA was inhibited 50% by the membrane permeable Ca2+ chelator, 1,2-bis(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM) or calpain inhibitor I. These data demonstrate that intracellular free calcium and the calcium-dependent protease, calpain play critical roles in monocytic differentiation. Intracellular calcium appears to be most critical in the 1,25D(3)-priming stage of differentiation, while calpain is essential in the TPA maturation response.